Editing in dsp quattro5/29/2023 ![]() ![]() ![]() If confirmed, endocrine symptoms may be a proxy for tamoxifen response and useful for patients and providers to encourage adherence. Further studies are needed to assess whether these observations predict clinical outcomes. Emergent/worsening endocrine symptoms are associated with significant, early declines in breast density after tamoxifen initiation. Density declines remained among women with detectable tamoxifen metabolites or intermediate/efficient CYP2D6 metabolizer status. Similar declines were observed with increasing symptom frequency ( p-trends for no symptoms = 0.91 low/moderate symptoms = 0.03 high symptoms = 0.004). ![]() Using multivariable linear regression, we estimated mean change in breast density by treatment-associated endocrine symptoms adjusting for age, race, menopausal status, body mass index, and baseline density. CYP2D6 status was genotyped, and tamoxifen metabolites were measured at T3. Treatment-associated endocrine symptoms and sound speed measures of breast density, assessed via novel whole breast ultrasound tomography (m/s), were ascertained before tamoxifen (T0) and at 1–3 (T1), 4–6 (T2), and 12 months (T3) after initiation. We evaluated treatment-associated endocrine symptoms and breast density change among 74 women prescribed tamoxifen in a 12-month longitudinal study. However, it is unknown whether endocrine symptoms are associated with reductions in breast density after tamoxifen initiation. Although breast density decline with tamoxifen therapy is associated with greater therapeutic benefit, limited data suggest that endocrine symptoms may also be associated with improved breast cancer outcomes. ![]()
0 Comments
Leave a Reply. |